New pill takes on bile duct cancer: phase 3 trial launches
NCT ID NCT07328919
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests a new daily pill, TT-00420, against standard chemotherapy in 138 adults with advanced bile duct cancer that has a specific genetic change (FGFR2 fusion or mutation) and has worsened after first treatment. The study compares how long the cancer stays under control and overall survival. It is open-label, meaning everyone knows which treatment they receive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TT-00420 (tinengotinib) tablets
What this could lead to
If successful, this could provide a new targeted treatment option for people with a specific type of advanced bile duct cancer that has stopped responding to initial chemotherapy.
What could go wrong
This is an early-stage Phase 3 trial with only 138 participants, so results may not apply to all patients. The drug may not prove more effective than chemotherapy and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INTRAHEPATIC CHOLANGIOCARCINOMA (ICC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Anhui Provincial Hospital
Hefei, Anhui, China
-
Beijing Cancer Hospital
Beijing, China
Contact
-
Beijing Tsinghua Changgung Hospital
Beijing, China
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, China
-
Eastern Hepatobiliary Surgery Hospital
Shanghai, China
-
Fudan University Shanghai Cancer Hospital
Shanghai, China
-
Fujian Cancer Hospital
Fuzhou, Fujian, China
-
Hunan Cancer Hospital
Changsha, Hunan, China
-
Jinan Central Hospital
Jinan, Shandong, China
-
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
-
Peking Union Medical College Hospital
Beijing, China
-
Shandong Cancer Hospital
Jinan, Shandong, China
-
Sichuan Cancer Hospital
Chengdu, Sichuan, China
-
The First Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, China
-
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
-
West China Hospital of Sichuan University
Chengdu, Sichuan, China
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
-
Zhongnan hospital of Wuhan University
Wuhan, Hubei, China
-
Zhongshan Hospital, Fudan University
Shanghai, China
-
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China